Key Trends Influencing the Growth of the Oral Biologics & Biosimilar Drugs Market in 2025: The Emergence Of New Insulin Biosimilars In The Oral Biologics And Biosimilar Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Oral Biologics & Biosimilar Drugs Market Through 2025?
The market size for oral biologics and biosimilar drugs has seen a rapid expansion in the past few years. The market, which is projected to grow from a volume of $7.19 billion in 2024 to $8.6 billion in 2025, boasts a compound annual growth rate (CAGR) of 19.6%. Factors such as an increasing occurrence of chronic illnesses, heightened awareness of oral biologics, a surge in patent expirations and a growing demand for biosimilars have contributed to the extraordinary growth during the past period.

What's the Projected Size of the Global Oral Biologics & Biosimilar Drugs Market by 2029?
The market for oral biologics & biosimilar drugs is projected to witness a remarkable surge, expanding to a value of $15.11 billion in 2029 with a compound annual growth rate (CAGR) of 15.1%. The projected growth within the forecast period can be associated with a number of factors including the rise of targeted therapy, an escalating emphasis on preventive medicine, growing healthcare expenditure and an aging demographic. Key trends within the predicted timescales comprise advancements in oral delivery systems, the development of orally administered biologics, the evolution of biosimilar innovations, and a shift towards more patient-focused care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Top Growth Drivers in the Oral Biologics & Biosimilar Drugs Industry: What's Accelerating the Market?
The escalating incidence of chronic illnesses such as arthritis, asthma, and cancer is foreseen to be a pivotal catalyst propelling the oral biologics and biosimilar marketplace. Factors such as excessive working hours, limited physical movement, and unhealthy dietary and drinking habits contribute to the surge in chronic illnesses. The utilization of biologics for the treatment of these chronic diseases is on the rise. Biologics boost the immune system response to cancer cells which aids in their elimination from the body. For instance, a United Nations article from May 2023 speculated that by 2030, chronic diseases will account for 70% of global deaths. The global impact of chronic diseases is expected to hit around 60%. Therefore, the upsurge in the incidence of chronic diseases may drive up the demand for biologics and biosimilars, thereby fuelling the growth of the oral biologics & biosimilar drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Trends Will Shape the Oral Biologics & Biosimilar Drugs Market Through 2029 and Beyond?
The most recent development in the oral biologics and biosimilar market is the introduction of novel insulin biosimilars. The predominant players in this market are channeling resources into the production of an insulin biosimilar alternative. This, in turn, is fostering competitive dynamics among various biosimilar manufacturers. For example, Eli Lilly and Company, a U.S. firm engaged in the production of oral biologics and biosimilar medicines, launched an insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr) in April 2023. Insulin glargine products, such as this, are employed to boost glycemic control in adults, children, and infants with type 1 diabetes, and adults with type 2 diabetes.

What Are the Main Segments in the Oral Biologics & Biosimilar Drugs Market?
The oral biologics & biosimilar drugs market covered in this report is segmented -

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3792&type=smp

Which Top Companies are Driving Growth in the Oral Biologics & Biosimilar Drugs Market?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

Which Regions Will Dominate the Oral Biologics & Biosimilar Drugs Market Through 2029?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.